InvestSMART

Chimeric Therapeutics Limited (ASX:CHM)

ALERT: Price-sensitive ASX Announcement for CHM
Current share price for CHM : $0.055 -0.045 (-45%)+
Announcement
Release
1 Jun 2026 8:27AM
Price at Release
$0.100
Full Release
download
Summary
Chimeric Therapeutics announced promising results from their Phase 1/2 study of CHM CDH17, a novel CAR-T cell therapy, at the ASCO conference. The study showed that 82% of evaluable patients achieved stable disease according to RECIST criteria, with CHM CDH17 expanding and persisting in the peripheral blood of all treated patients, indicating its tolerability and potential efficacy in heavily pre-treated metastatic patients. The trial continues to enroll patients at Dose Level 3, with a recommended Phase 2 dose expected. This therapy targets advanced colorectal, gastric, and intestinal neuroendocrine tumors by focusing on the CDH17 cancer biomarker.
Key Points
  • Chimeric Therapeutics announced positive Phase 1/2 data for CHM CDH17 at ASCO.
  • 82% of evaluable patients achieved stable disease per RECIST criteria.
  • CHM CDH17 showed expansion and persistence in peripheral blood of all treated patients.
  • CHM CDH17 is tolerable in heavily pre-treated metastatic patients.
  • Ongoing enrollment at Dose Level 3 with an anticipated Phase 2 dose recommendation.
  • The trial targets advanced colorectal, gastric, and intestinal neuroendocrine tumors.
  • CHM CDH17 is a novel CAR-T cell therapy targeting CDH17, a cancer biomarker.
  • The trial seeks to determine the recommended Phase 2 dose and evaluate objective response rate.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.